Ancilia Biosciences develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
The company is developing a proprietary platform that leverages the natural function of CRISPR to produce a new class of live biotherapeutics (LBPs) with engineered immunity to viral phages. These viral phages, or bacteriophages, comprise approximately half of the gut microbiome. Ancilia says that there is evidence that they contribute to disease and potentially limit the efficacy of LBPs.
The Ancilia platform is being developed as an essential enabling technology that identifies potentially problematic viruses in the gut using a proprietary approach to viral characterization. It then leverages the natural immune function of CRISPR to produce a new class of live biotherapeutics with immunity to these viruses.
Ancilia’s scientists have demonstrated proof of principle and filed key patents for the technology. The company’s founders and advisers include scientific leaders across CRISPR and the virome, including CSO Rodolphe Barrangou, PhD, a CRISPR pioneer who is a co-founder of Intellia Therapeutics and a former chairman of Caribou Biosciences.
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …